Table 1 Sequence analysis of V gene rearrangements amplified from DLBCL and HRS cells of a composite lymphoma
Cells | Cells positive in PCR | PCR products amplified repeatedly | Original rearrangement potentially functional | Mutation frequency (%) | Functionality after somatic hypermutation | Ongoing mutation |
|---|---|---|---|---|---|---|
DLBCL | ||||||
CD20+ (2–4 cells/tube) | VHL: 14/20 | 14 × VH3–23a | + | 27–28b | − | No |
VHFRIc: 0/20 | ||||||
Vκ: 10/20 | 10 × Vκ1D–39 | + | 18 | + | No | |
Vλ: 1/20d | ||||||
DH: 7/10 | 7 × unrearranged | |||||
KDE: 18/20 | 18 × unrearrangede | |||||
Negative controlsf | VHL, KDE, DH: 0/4 | |||||
VHL, KDE: 0/4 | ||||||
VHFRI, Vκ, Vλ: 0/8 | ||||||
CD20+ (1 cell/tube) | VHL: 18/42 | 18 × VH3–23 | + | 27–28b | − | No |
Negative controlsf | VHL: 0/18 | |||||
HL | ||||||
CD30+ (1 cell/tube) | VHL: 8/16 | 8 × VH3–23 | + | 7 | + | No |
VHFRI: 14/20 | 14 × VH3–23 | + | 7 | + | No | |
Vκ: 15/20g | 6 × Vκ1D–39h | + | 7 | + | No | |
14 × Vκ1D–6 | + | 8 | + | No | ||
Vλ: 1/20d | ||||||
DH: 4/10 | 4 × unrearranged | |||||
KDE: 13/16 | 10 × unrearranged | |||||
11 × Jκ−Cκ intron–RSS/KDE rearrangement | ||||||
Negative controlsf | VHL, KDE, DH: 0/4 | |||||
VHL, KDE: 0/2 | ||||||
VHFRI, Vκ, Vλ: 2/8i |